原发性肝癌患者血清miR-145、miR-934、AFP、TK1水平与临床病理特征及预后的关系

doi:10.3969/j.issn.1006-5725.2026.07.010

Abstract

Abstract:

Objective To explore the relationship between the levels of serum MicroRNA （miR）-145， miR-934， Alpha-fetoprotein （AFP）， and Thymidine kinase 1 （TK1） in patients with primary liver cancer， as well as their associations with the clinicopathological characteristics and prognosis. Methods From September 2021 to September 2023， 202 cases of primary liver cancer patients admitted to Qingdao Central Hospital， University of Health and Rehabilitation Sciences were selected as the liver cancer group. Meanwhile， 205 patients with liver cirrhosis during the same period were selected as the liver cirrhosis group， and 213 healthy individuals undergoing physical examinations were selected as the control group. Among them， the liver cancer group was further divided into the poor-outcome group and the good-outcome group according to the prognosis 3 months after surgery， with 56 cases in the poor-outcome group and 146 cases in the good-outcome group respectively. After discharge， patients were followed up every three months， and the follow-up period ended in September 2025 or upon the patient's death. The clinical data of all the research subjects were statistically analyzed. The levels of serum miR-145， miR-934， AFP， and TK1 were compared among the liver cancer group， liver cirrhosis group， control group， poor-outcome group， good-outcome group， and patients with primary liver cancer with different clinicopathological characteristics. The predictive value of combined detection of different serum indicators for the poor prognosis of patients with primary liver cancer was analyzed using the receiver operating characteristic curve （ROC）. Additionally， the Kaplan-Meier survival curve was drawn to analyze the overall survival of patients with primary liver cancer at different expression levels of serum indicators. Results The serum miR-145 level in the liver cancer group was significantly lower than those in the liver cirrhosis group and the control group. In contrast， the levels of miR-934， AFP， and TK1 were higher than those in the liver cirrhosis group and the control group （P < 0.05）. Moreover， the levels of each index in the liver cirrhosis group were intermediate between those in the liver cancer group and the control group. The serum miR-145 level in patients with TNM stage Ⅲ and poorly differentiated primary liver cancer was lower than that in patients with TNM stage Ⅰ—Ⅱ and moderately to highly differentiated primary liver cancer （P < 0.05）. The levels of serum AFP and TK1 in patients with TNM stage Ⅲ and poorly differentiated primary liver cancer were higher than those in patients with TNM stage Ⅰ—Ⅱ and moderately to well-differentiated primary liver cancer （P < 0.05）. The serum miR-934 level in patients with TNM stage Ⅲ primary liver cancer was higher than that in patients with TNM stage Ⅰ—Ⅱ primary liver cancer （P < 0.05）. The serum miR-145 level in the poor-outcome group was lower than that in the good-outcome group， whereas the other three indicators were higher （all P < 0.05）. ROC curve analysis demonstrated that the area under the curve （AUC） for the combined prediction of poor prognosis by the four indicators was 0.897 （95%CI： 0.846 ~ 0.935）， with a sensitivity of 83.93% and a specificity of 86.99%， which was superior to any single indicator （P < 0.05）. The median follow-up time was 35 months （range： 3 to 48 months）. Survival analysis indicated that the overall survival period was longer in the miR-145 high-expression group （hazard ratio 0.669， 95%CI： 0.475 ~ 0.943， P = 0.022）， while the overall survival periods were longer in the miR-934， AFP， and TK1 low-expression groups （hazard ratio 0.707， 95%CI： 0.506 ~ 0.987； hazard ratio 0.700， 95%CI： 0.501 ~ 0.978； hazard ratio 0.627， 95%CI： 0.428 ~ 0.917； all P < 0.05）. Conclusions miR-145 exhibited low expression in the serum of patients with primary liver cancer， whereas miR-934， AFP， and TK1 showed high expression in the serum of these patients. These four indicators were closely associated with the clinicopathological characteristics and poor prognosis of patients with primary liver cancer. Furthermore， the combined detection of these four indicators holds high predictive value for the poor prognosis of patients with primary liver cancer and may offer a new biomarker combination for prognosis assessment.

Key words: primary liver cancer, pathological features, prognosis, microrna-145, microRNA-934, alpha-fetoprotein, thymidine kinase 1

CLC Number:

R735.7

Yahong NIE,Meiyu ZHAO,Chengyu SHI,Shan LIU. The relationship between serum miR-145， miR-934， AFP， TK1 levels and clinicopathological characteristics and prognosis in patients with primary liver cancer[J]. The Journal of Practical Medicine, 2026, 42(7): 1183-1191.

Figures/Tables 9

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

Tab.6

Tab.7

Fig.1

Fig.2

References 29

[1]	HONG Z. Research progress of Chinese medicine in the treatment of primary liver cancer［J］. JCTT， 2025， 3（2）： 48-51. doi： 10.3736/jcim20050620 . doi: 10.3736/jcim20050620
[2]	Li S J， SHEN H， ZHANG S C， et al. Research progress of acupuncture and moxibustion in treatment of primary liver cancer and its related complications［J］. Acupunct Res， 2025， 50（5）： 605-612. doi： 10.13702/j.1000-0607.20240053 . doi: 10.13702/j.1000-0607.20240053
[3]	ALMOHAMMADI N H. Liver cancer in Saudi Arabia： A registry-based nationwide descriptive epidemiological and survival analysis［J］. Cancer epidemiol， 2025， 94（18）： 91-94. doi： 10.1016/j.canep.2024.102731 . doi: 10.1016/j.canep.2024.102731
[4]	WASEEM H B， SHAKEEL M， HASSAN F U， et al. In silico Identification and Computational Screening of Potential AFP Inhibitors Against Liver Cancer［J］. Med Chem， 2025， 21（6）： 10-12. doi： 10.2174/0115734064330103250106034126 . doi: 10.2174/0115734064330103250106034126
[5]	HAYAT A. New Insights on the Roles of miR-21 in Cancer Development and Proliferation［J］. Proc Anticancer Res， 2024， 8（6）： 53-66. doi：10.26689/par.v8i6.8160 . doi: 10.26689/par.v8i6.8160
[6]	LAI Y， LIU J， HU X， et al. Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3［J］. Cell Journal， 2023， 25（8）： 48-51. doi： 10.22074/cellj.2023.1995666.1251 . doi: 10.22074/cellj.2023.1995666.1251
[7]	李明，王华，张磊，等. miR-4262、miR-934与原发性肝癌临床病理特征及其预后的关系［J］. 中华肝脏病杂志， 2023， 31（5）： 389-395. doi： 10.14000/j.cnki.issn.1008-1704.2025.08.013 . doi: 10.14000/j.cnki.issn.1008-1704.2025.08.013
[8]	张晓华，李素娟，侯得山，等. 血清Smad4、TK1、VEGF对原发性肝癌诊断及预后评估的临床价值分析［J］. 中国肿瘤临床， 2024， 51（18）： 945-950. doi： 10.3969/j.issn.1674-1129.2023.04.030 . doi: 10.3969/j.issn.1674-1129.2023.04.030
[9]	国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范（2019年版）［J］. 中华肝脏病杂志， 2020， 28（2）： 112-128. doi： 10.3760/cma.j.issn.1673-9752.2020.01.001 . doi: 10.3760/cma.j.issn.1673-9752.2020.01.001
[10]	中国抗癌协会肝癌专业委员会. 原发性肝癌规范化病理诊断指南（2015年版）［J］. 中华肝胆外科杂志， 2015， 21（3）： 145-151. doi： 10.11855/j.issn.0577-7402.2015.11.03 . doi: 10.11855/j.issn.0577-7402.2015.11.03
[11]	European Association for the Study of the Liver （EASL）. EASL Clinical Practice Guidelines： Management of cirrhosis and its complications［J］. J Hepatol， 2018， 69（2）： 406-460. doi： 10.1016/j.jhep.2018.03.024 . doi: 10.1016/j.jhep.2018.03.024
[12]	American Joint Committee on Cancer. AJCC Cancer Staging Manual［M］. 8th ed. Cham： Springer Int Publ， 2017 doi： 10.1097/SLA.0000000000003071 . doi: 10.1097/SLA.0000000000003071
[13]	ZHAO X， LIU J， CHEN M， et al. Selection and validation of reference genes for serum microRNA detection［J］. J Laborat Med， 2019， 42（3）： 215-220. doi： 10.1016/j.plaphy.2011.10.010 . doi: 10.1016/j.plaphy.2011.10.010
[14]	JIANG L， ZHAO N， XU J， et al. Incidence trends of primary liver cancer in different geographical regions of China from 1978 to 2012 and projections to 2032： An age‐period‐cohort analysis［J］. J Inter Cancer， 2024， 154（3）： 465-476. doi： 10.1002/ijc.34724 . doi: 10.1002/ijc.34724
[15]	XIANG Z， HUANG Y， MA J， et al. Temporal trends of incidence， mortality， and survival of liver cancer during 2011–2020 in Fujian Province， Southeast China［J］. Arch Public Health， 2024， 82（1）： 1-10. doi： 10.1186/s13690-024-01462-7 . doi: 10.1186/s13690-024-01462-7
[16]	GUANGCAI N， GANG C. Risk factors and prognosis of postoperative intraperitoneal seeding in primary liver cancer patients［J］. JPO， 2024， 39（1）： 22-24. doi： 10.13267/j.cnki.syzlzz.2024.008 . doi: 10.13267/j.cnki.syzlzz.2024.008
[17]	ZHU S， JIN Y， ZHOU M， et al. KK-LC-1， a biomarker for prognosis of immunotherapy for primary liver cancer［J］. BMC Cancer， 2024， 24（1）： 36-38. doi： 10.1186/s12885-024-12586-y . doi: 10.1186/s12885-024-12586-y
[18]	沈未，鲁迪，徐骁. 肝癌肝移植适应证的科学演进［J］. 器官移植， 2025， 16（2）： 202-207. DOI： 10.12464/j.issn.1674-7445.2025064 . doi: 10.12464/j.issn.1674-7445.2025064
[19]	LIU Y， JIANG W， LI X， et al. The Diagnostic Performance of AFP， AFP-L3， DCP， CA199， and Their Combination for Primary Liver Cancer［J］. J Hepatocell Carcinoma， 2025， 12（1）： 64-66. doi： 10.2147/JHC.S499966 . doi: 10.2147/JHC.S499966
[20]	SHA M， ZHANG J， LIU J K， et al. Inhibiting Pyk2/Src expression by miR-23b-3p suppressed liver cancer stem cell function and hepatic carcinoma progression［J］. Cancer Cell Int， 2025， 25（1）： 6-8. doi： 10.1186/s12935-025-03841-8 . doi: 10.1186/s12935-025-03841-8
[21]	KORDKATOULI M， SATEEI A， JAFARI A， et al. Exploring the Role of MiR-373 in Colorectal Cancer Development and Progression［J］. Gene Cell Tissue， 2025， 12（2）： 90-93. doi：10.5812/gct-159893 . doi: 10.5812/gct-159893
[22]	CHU D X， JIN Y， WANG B R， et al. LncRNA HOTAIR Enhances Epithelial-to-mesenchymal Transition to Promote the Migration and Invasion of Liver Cancer by Regulating NUAK1 via Epigenetic Inhibition miR-145-5p Expression［J］. J Cancer， 2023， 14（12）： 332-335. doi： 10.7150/jca.85335 . doi: 10.7150/jca.85335
[23]	鲁建锋，蔡莹，徐佳灵，等. miR-934、UbcH10、外周血T淋巴细胞亚群在原发性肝癌早期诊断及预后评估中的应用价值［J］. 中西医结合肝病杂志， 2023， 33（11）： 976-980. doi： 10.3969/j.issn.1005-0264.2023.011.004 . doi: 10.3969/j.issn.1005-0264.2023.011.004
[24]	韩廷超，王忠，申梦圆，等. 载药微球对比碘化油肝动脉化疗栓塞联合局部热消融治疗巨块型肝癌的疗效分析［J］. 介入放射学杂志， 2024， 33（9）： 989-994. doi： 10.3969/j.issn.1008-794X.2024.09.012 . doi: 10.3969/j.issn.1008-794X.2024.09.012
[25]	燕彩霞，王达，魏传霞，等. 酸味方对原发性肝癌经导管肝动脉化疗栓塞术后血清AFP，CEA，CA-125及CD_（4）^（+）/CD_（8）^（+）水平的影响［J］. 中华中医药学刊， 2024， 42（8）： 98-102. doi： 10.13193/j.issn.1673-7717.2024.08.021 . doi: 10.13193/j.issn.1673-7717.2024.08.021
[26]	TANG S， LIU H， CHEN P， et al. Analysis on the value of soluble intercellular adhesion molecule-1 （sICAM-1）， alpha fetoprotein （AFP）， and aspartate aminotransferase/platelet ratio index （APRI） in predicting the prognostic survival of patients with primary liver cancer after radiofrequency ablation［J］. Am J Transl Res， 2024， 15（1）： 5004-5010. doi： 10.21037/apm-21-749 . doi: 10.21037/apm-21-749
[27]	刘杰，董浩. miR-4262，miR-934与原发性肝癌临床病理特征及其预后的关系［J］. 肝脏， 2025， 30（8）： 1097-1100. doi： 10.3969/j.issn.1008-1704.2025.08.018 . doi: 10.3969/j.issn.1008-1704.2025.08.018
[28]	鲁建锋，蔡莹，徐佳灵，等. miR-934，UbcH10，外周血T淋巴细胞亚群在原发性肝癌早期诊断及预后评估中的应用价值［J］. 中西医结合肝病杂志， 2023， 33（11）： 976-980. doi： 10.3969/j.issn.1005-0264.2023.011.004 . doi: 10.3969/j.issn.1005-0264.2023.011.004
[29]	MARKERS D. The Value of MRI Combined with AFP， AFP-L3， GP73， and DCP in the Diagnosis of Early Primary Liver Cancer［J］. Dis Markers， 2023， 3（22）： 620-623. doi： 10.1155/2023/9815623 . doi: 10.1155/2023/9815623

基因名称	引物	碱基序列
miR-145	5'-ACACTCCAGCTGGGGTCCAGTTTTCCCAGGA-3'	31
miR-145	5'-CTCAACTGGTGTCGTGGA-3'	18
miR-934	5'-GCCTAGAAACATCCTGCCGG-3'	20
miR-934	5'-AGGCCATGTGTCGTGGTCG-3'	19
U6	5'-ATTGCAACCATACACACAACATT-3'	23
U6	5'-GCAACGCTTCACGAATTTG-3'	19

临床特征	肝癌组（n = 202）	肝硬化组（n = 205）	对照组（n = 213）	χ²/F值	P值
年龄/岁	55.08 ± 6.29	53.96 ± 6.35	53.78 ± 7.01	2.359	0.095
性别/[例（%）]				0.386	0.824
男	105（51.98）	111（54.15）	117（54.93）
女	97（48.02）	94（45.85）	96（45.07）
BMI/（kg/m²）	23.07 ± 1.07	22.77 ± 1.35	22.89 ± 1.49	2.667	0.070
肿瘤最大径/[例（%）]				-	-
≤ 5 cm	85（42.08）	-	-
> 5 cm	117（57.92）	-	-
TNM分期/[例（%）]				-	-
Ⅰ—Ⅱ级	174（86.14）	-	-
Ⅲ级	28（13.86）	-	-
分化程度/[例（%）]				-	-
低分化	53（26.24）	-	-
中高分化	149（73.76）	-	-

指标	肝癌组（n = 202）	肝硬化组（n = 205）	对照组（n = 213）	F值	P值
miR-145	0.73 ± 0.16	1.21±0.38^*	1.51 ± 0.42^*#	273.800	< 0.001
miR-934	3.01 ± 0.96	2.19±0.77^*	1.23 ± 0.36^*#	304.824	< 0.001
AFP/（ng/mL）	297.28 ± 63.39	84.89 ± 20.54^*	35.86 ± 10.83^*#	2 661.415	< 0.001
TK1/（pmol/L）	4.09 ± 1.06	2.57±0.72^*	1.77 ± 0.37^*#	490.105	< 0.001

临床病理特征/指标	例数	miR-145	t值	P值	miR-934	t值	P值
肿瘤最大径			1.764	0.079		1.539	0.125
≤ 5 cm	85	0.76 ± 0.25			2.93 ± 0.91
> 5 cm	117	0.70 ± 0.23			3.14 ± 0.99
TNM分期			7.559	0.001		4.734	0.001
Ⅰ—Ⅱ级	174	0.98 ± 0.23			2.68 ± 0.74
Ⅲ级	28	0.63 ± 0.21			3.41 ± 0.86
分化程度			9.644	0.001		1.606	0.110
低分化	53	0.58 ± 0.18			3.12 ± 1.00
中高分化	149	0.99 ± 0.29			2.88 ± 0.91

临床病理特征/指标	例数	AFP/（ng/mL）	t值	P值	TK1/（pmol/L）	t值	P值
肿瘤直径			0.186	0.852		0.588	0.543
≤ 5 cm	85	296.68 ± 88.38			4.02 ± 1.27
> 5 cm	117	299.06 ± 90.48			4.12 ± 1.31
TNM分期			1.859	0.001		6.822	0.001
Ⅰ—Ⅱ级	174	288.49 ± 82.32			3.16 ± 1.05
Ⅲ级	28	319.86 ± 86.41			4.63 ± 1.11
分化程度			4.536	0.001		3.684	0.001
低分化	53	325.33 ± 102.53			4.61 ± 1.32
中高分化	149	262.58 ± 80.11			3.85 ± 1.20

The relationship between serum miR-145， miR-934， AFP， TK1 levels and clinicopathological characteristics and prognosis in patients with primary liver cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 9

References 29

Related Articles 15

Recommended Articles

Metrics

Comments

指标	预后不良组（n = 56）	预后良好组（n = 146）	t值	P值
miR-145	0.57 ± 0.18	0.77 ± 0.22	6.066	< 0.001
miR-934	3.43 ± 0.89	2.72 ± 0.89	5.075	< 0.001
AFP/（ng/mL）	334.17 ± 79.56	268.73 ± 77.34	5.234	< 0.001
TK1/（pmol/L）	4.28 ± 1.06	3.39 ± 1.09	5.341	< 0.001

指标	敏感度/%	特异度/%	AUC	95%CI	截断值	P值
miR-145	76.79	65.07	0.750^a	0.685 ~ 0.809	≤ 0.72	< 0.001
miR-934	76.79	63.01	0.745^a	0.679 ~ 0.804	> 3.03	< 0.001
AFP	75.00	60.96	0.715^a	0.647 ~ 0.776	> 285.03 ng/mL	< 0.001
TK1	60.70	74.00	0.708^a	0.640 ~ 0.770	> 4.12 pmol/L	< 0.001
联合	83.93	86.99	0.897	0.846 ~ 0.935	> 13.00	< 0.001

[1]	Chunming WU,Wen CHENG,Zhengguo ZHANG,Yan JIANG,Jun SUN. Relationship between CURB-65 score， serum IL-6， PCT/ALB ratio and prognosis in patients with severe pneumonia [J]. The Journal of Practical Medicine, 2026, 42(6): 923-929.
[2]	Bin YU,Jian ZHOU,Tian TIAN,Fusheng WANG. The efficacy of bevacizumab combined with chemotherapy in the treatment of postoperative patients with oligometastatic colorectal cancer and its impact on mpfs median progression-free survival [J]. The Journal of Practical Medicine, 2026, 42(5): 750-758.
[3]	Zhenggang WANG,Hui XIONG,Ting HE,Xiaojing LIU,Yanhua YE. Serum melatonin and IGFBP3 levels in the diagnosis and prognostic evaluation of age⁃related cataract [J]. The Journal of Practical Medicine, 2026, 42(5): 831-837.
[4]	Jinsong LI,Senxin HUA,Ludan HUANG,Qing SU. Changes in serum levels of NRG-1， CHIT1， Cx43， and MECP2 in patients with acute cerebral infarction and their relationship with severity and prognosis [J]. The Journal of Practical Medicine, 2026, 42(4): 691-697.
[5]	Jianhua JIAO,Ruixue MA,Honghong GU,Xing WU,Xiuli CAO. Evaluation value of sCD163， SHR， pro-ADM， PTX3 combined with score of chest CT on the condition and prognosis of elderly patients with stroke-related pneumonia [J]. The Journal of Practical Medicine, 2026, 42(3): 447-454.
[6]	Jianxia HUANG,Guoliang ZHANG,Jushan ZHANG,Yan WANG,Qing WU,Binzhang WU,Minghu DU,Yuxia WANG. The relationship between levels of serum MuC1， PINP， sFLC and clinical staging， immunophenotyping in patients with multiple myeloma and their predictive value for prognosis [J]. The Journal of Practical Medicine, 2026, 42(3): 504-510.
[7]	Pengzheng LI,Baoguo CHENG,Jinzhan LIU,Weixing LI. Application of CT perfusion parameters and serum CEA/AFP in monitoring post-TACE recurrence in primary hepatocellular carcinoma [J]. The Journal of Practical Medicine, 2026, 42(2): 176-184.
[8]	Wen LI,Haisheng HUANG,Bin HUANG,Li HAN. Expression correlation of PD⁃L1 and Her⁃2 in invasive urothelial carcinoma and their impact on prognosis [J]. The Journal of Practical Medicine, 2026, 42(2): 194-200.
[9]	Xin LIU,Hongrui ZHANG,Ying SHEN,Yuqiao DIAO,Tao FAN. Correlation of serum lncRNA THRIL， lncRNA NEAT1 with the severity and prognosis of neonatal pneumonia [J]. The Journal of Practical Medicine, 2026, 42(2): 327-333.
[10]	Xinghua BIAN,Peng XU,Junfei SHI,Zhenhua MA. The predictive value of serum matrix metalloproteinase-2， myeloperoxidase， axonal guidance factor 3E for the prognosis of patients undergoing intracranial aneurysm clipping surgery under general anesthesia [J]. The Journal of Practical Medicine, 2026, 42(1): 56-63.
[11]	Yingdao CHEN,Haining LI,Yuying LI,Qiping ZHANG,Bingsong LIANG,Guohui. LI. The predictive value of serum miR-143-3p and miR-188-5p levels for poor prognosis in patients with acute cerebral infarction after thrombolysis [J]. The Journal of Practical Medicine, 2025, 41(8): 1117-1122.
[12]	Juan SHEN,Yong WANG,Qiuping WANG,Chen. LING. Relationship between the immune status of patients with multiple myeloma and the changes in the levels of detection of peripheral blood RDW-SD， sBCMA， sFLCR and prognosis [J]. The Journal of Practical Medicine, 2025, 41(8): 1161-1166.
[13]	Yin GUO,Haiqing REN,Xiaoyang GUO,Jianghua ZUO,Ting. WANG. Study on the correlation between serum APRIL， PLA2R⁃Ab， and 25⁃（OH） D₃ levels and the severity and prognosis of primary membranous nephropathy [J]. The Journal of Practical Medicine, 2025, 41(8): 1199-1204.
[14]	Weixiang FENG,Juan WANG,Yanbin SONG,Sheliang XUE,Wenhua LI. The long⁃term prognosis of nonparoxysmal atrial fibrillation （NPAF） patients after radiofrequency catheter ablation [J]. The Journal of Practical Medicine, 2025, 41(7): 1036-1043.
[15]	Fuxia ZHENG,Lijun MIAO,Fengxiang HUANG,Shifu HUANG,Zengyan GAO,Ruixia ZHANG,Yong MENG. The correlation between the levels of APC， TXB2， and sB7⁃H3 in peripheral blood of elderly patients with pneumonia and the severity and prognosis of the disease [J]. The Journal of Practical Medicine, 2025, 41(7): 1056-1061.